Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

2.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. 
Via Benzinga
Topics Stocks
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
From Caribou Biosciences, Inc.
Via GlobeNewswire
Where Caribou Biosciences Stands With Analysts
 
Via Benzinga
2 Stocks I'm Buying on the Dip This Week
Caribou Biosciences and AT&T screen as incredible bargains for patient investors. 
Via The Motley Fool
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Top Growth Stocks to Buy Right Now Without Hesitation
These stocks are dirt cheap right now. 
Via The Motley Fool
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
From Caribou Biosciences, Inc.
Via GlobeNewswire
2 Exciting Biotech Stocks to Buy With Less Than $10
You can pick up these stocks for a song right now. 
Via The Motley Fool
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Wall Street price targets suggest this stock can rocket more than 400% higher. 
Via The Motley Fool
2 Magnificent Growth Stocks to Buy On the Dip
It might be time to catch these falling knives. 
Via The Motley Fool
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
From Caribou Biosciences, Inc.
Via GlobeNewswire
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
Early-stage biotechs almost never warrant this level of enthusiasm. 
Via The Motley Fool
NXP Semiconductors To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Wednesday
HC Wainwright & Co. cut the price target for Caribou Biosciences, Inc. (NASDAQ: CRBU) from $25 to $23. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Caribou Biosciences shares fell... 
Via Benzinga
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
Simplifying the cell therapy manufacturing process could be worth a lot of money. 
Via The Motley Fool
Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years
It's still early going, but this small biotech shows great promise. 
Via The Motley Fool
2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street
The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future. 
Via The Motley Fool
MarketBeat Week in Review – 7/10 - 7/14
As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week 
Via MarketBeat
Topics Economy
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement. 
Via Benzinga
Caribou Biosciences Raises $125M Via Equity Just One Week After Pfizer Invested $25M
Caribou Biosciences Inc (NASDAQ: CRBU) reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.